Accused of forging a seal, achieving a sales volume of 0.117 billion in two years. Jimin Health is suing its own vice president. Can Dealers get their payment back? | Quick read announcement.

① The stamp of Jimin Health is identified as "forged," and the investigation revealed the existence of a "supplementary agreement"; ② Jimin Health is at risk of being sued by Dealers, stating that "it will actively communicate with the involved Dealers to seek a proper solution"; ③ The industry believes that the involved vice president may have undertaken a considerable sales task, thus "taking a risk," while it's very difficult for suppliers to recover the payments in the short term.

cls.cnMar 26 11:33 ET

0.124 billion USD! FOSUN PHARMA and United Family Healthcare "completely part ways" | Quick announcement.

① FOSUN PHARMA's subsidiary plans to sell a 6.6% stake in the symbol company for 0.124 billion USD; ② The relationship between FOSUN PHARMA and Huameijia can be traced back to 2009; ③ After this Trade is completed, FOSUN PHARMA will completely exit Huameijia.

cls.cnMar 13 11:26 ET

Guizhou Xinbang Pharmaceutical's subsidiary is embroiled in a bribery scandal; what is the impact?

① Company personnel stated that this matter currently has no impact on the company's operation, and the subsidiary mainly engages in in-hospital pharmaceutical wholesale. Even if penalized later, it will not involve qualification issues. ② Industry experts believe that the short-term impact is significant, while the long-term impact is minimal. In the short term, the principal company may be listed as untrustworthy due to the crime of unit bribery, which would exclude it from the bidding procurement of local hospitals in Guizhou for a period. However, in the long term, since it is not a quality issue, there are opportunities for repair.

cls.cnMar 4 09:08 ET

Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the

① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.

cls.cnMar 2 21:09 ET

Will pay over 30 million equity dispute amounts. Getein Biotech, Inc has issued multiple lawsuit announcements in the past four months | Brief announcement.

① Getein Biotech, Inc and nine minority shareholders of Jingchuan Diagnostics, including Wuhan Boruihong, have received a final judgment in their equity acquisition dispute. ② According to the judgment, Getein Biotech, Inc will pay over 30 million yuan for the acquisition.

cls.cnFeb 26 09:28 ET

To extend its Industry Chain layout, Sansure Biotech Inc. intends to acquire 54% equity in Hong'an Jiyuan, which has not yet turned a profit.

①Sansure Biotech Inc. stated that the company values the product's ease of operation, good stability, and high cost performance of Hong'an Jiyuan, making it suitable for projects in grassroots Medical Institutions; ②Since the launch of related products from Hong'an Jiyuan in 2024, thousands of blood analyzers have been installed in various provinces across the country within one year.

cls.cnFeb 25 22:29 ET